Literature reviews, generated by AI
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
6 free credits, then one-time credit packs from $5.
PTGS2, encoding cyclooxygenase-2 (COX-2), may influence pain through effects on prostaglandin production, inflammatory signaling, nociceptor activation, and neuronal sensitization. Available human evidence links PTGS2 variants with migraine susceptibility, cancer-pain severity, endometriosis-associated pain, postoperative and procedure-related pain, visceral hyperalgesia, osteoarthritis risk, headache duration, and response to COX-inhibiting analgesics. Reported variants include rs5277, rs1799964, rs5275, rs20417, rs689466, the −765G>C promoter polymorphism, and the −1195A/G promoter polymorphism. However, findings are heterogeneous, often based on small disease-specific studies, and generally do not directly measure pain thresholds, tolerance, or generalized nociceptive sensitivity. PTGS2 variation therefore remains a possible context-dependent modifier rather than an established universal biomarker of pain.
Question: PTGS2 genetic variants AND PAIN susceptibility and sensitivity
Read the full reviewPTGS2, encoding cyclooxygenase-2 (COX-2), contributes to inflammatory, neuropathic, and centrally maintained pain through prostaglandin production, particularly prostaglandin E₂ (PGE₂). COX-2-derived prostanoids sensitize peripheral nociceptors, while spinal and other central COX-2 pathways amplify nociceptive signaling and sustain hyperalgesia. Evidence from inflammatory models shows that selective COX-2 inhibition can suppress hyperalgesia even when oedema is minimally affected, supporting analgesic mechanisms beyond reduction of tissue swelling. Spinal COX-2/PGE₂ signaling also participates in diabetic neuropathy, injury-induced hyperalgesia, and centrally maintained hypersensitivity. However, the contribution of COX-2 varies with pain model, anatomical site, and treatment timing; it is especially prominent in central sensitization and early neuropathic pain, but is not required for every form of peripheral inflammatory hyperalgesia. These findings support COX-2 as an important but context-dependent analgesic target and motivate investigation of downstream PGE₂ synthases and receptors as potentially more selective alternatives to broad COX inhibition.
Question: PTGS2 AND PAIN
Read the full reviewNeuroplasticity reshapes how neural circuits represent, predict, perceive, and respond to temporal information. The supplied evidence indicates that experience-dependent plasticity can improve temporal discrimination, recalibrate subjective duration, adjust the rate of neural timekeeping, and organize the timing and sequencing of behavior. Auditory timing training is associated with neurochemical changes and improved performance in the inferior parietal cortex, implicating higher-order processes such as attention and temporal representation (PMID: 38316210). Reward-related dopamine signals may alter subjective timekeeping according to the timing of prediction errors and reward rates (PMID: 30864882). Plasticity also modifies neural integration windows, supports temporally structured activity during planning, and enables adaptation to changing information rates (PMID: 19582146; PMID: 26468192). In learning and rehabilitation, precisely timed feedback, repeated task-relevant practice, and circuit reorganization can improve the speed, consistency, and automatization of behavior (PMID: 41419090; PMID: 15831397; PMID: 42229417). However, the evidence concerns laboratory timing, neural learning, motor performance, and rehabilitation more directly than everyday scheduling or productivity. Neuroplasticity therefore provides an indirect biological basis for more adaptive temporal perception and behavioral timing rather than a demonstrated direct determinant of daily time management.
Question: how does neuroplasticity affect use of time?
Read the full reviewNo established treatment specifically targets or reverses Modic type 2 changes in patients with chronic sciatica or lumbar radiculopathy. These imaging findings may be associated with vertebral end-plate and adjacent marrow changes and can occur with degenerative disc disease, but they do not independently establish infection, nerve-root inflammation, or the source of sciatic symptoms. Management should therefore identify and treat the clinically concordant cause of radiculopathy, most often disc herniation or foraminal, lateral-recess, or central canal stenosis. Initial care is generally conservative and function-focused, with targeted injections considered for selected patients requiring short-term relief and decompression reserved for persistent disabling symptoms or neurological deterioration associated with confirmed nerve-root compression. Modic type 2 changes alone do not justify antibiotics, spinal fusion, or other invasive Modic-directed treatment.
Question: What's the best treatment for patients which type 2 Modic changes with chronic sciatica nerve inflammations
Read the full reviewResearch directly connecting guava (Psidium guajava) with medical technology is limited. The available evidence concerns medtech-adjacent applications, including glucose-management interventions, nutraceutical and botanical formulations, analytical quality-control methods, and biomedical assessment of therapeutic effects. A randomized clinical study found that a supercritical CO₂ guava fruit extract attenuated postprandial blood-glucose increases in healthy adults, while an experimental study of ethanolic guava leaf extract reported dose-dependent improvements in glucose and lipid profiles in diabetic rabbits, with higher doses also associated with protection against diabetes-related hepatic and renal injury (PMID: 31277259; PMID: 41689321). Additional work established an HPLC-DAD-ELSD method for quantifying nine guava triterpenoids and characterized polysaccharides with α-glucosidase-inhibitory and antioxidant activities (PMID: 32168948; PMID: 27083799). Guava bark and leaf extracts have also been evaluated in pain and osteoarthritis models using biomedical and histopathological technologies (PMID: 25386462; PMID: 28829233). Nevertheless, no identified study directly examined a medical device, diagnostic platform, sensor, or complete medtech system. Current evidence therefore supports guava primarily as a pharmacological, nutraceutical, analytical, or botanical component for future medtech-adjacent products.
Question: Medtech title guava
Read the full reviewLa extubación del paciente neurocrítico puede fracasar pese a una prueba de ventilación espontánea satisfactoria y a parámetros respiratorios convencionales adecuados. El resultado depende de la interacción entre la reserva respiratoria, el estado neurológico, la función bulbar, la protección de la vía aérea, la tos y el manejo de secreciones. La evidencia suministrada identifica como factores asociados con fracaso la tos débil o ausente, las secreciones moderadas o abundantes, la disfagia, la alteración de los reflejos protectores, un bajo componente motor del Glasgow, la ventilación mecánica prolongada y determinados indicadores de gravedad. Sin embargo, el Glasgow aislado, la modalidad de la prueba de ventilación espontánea y los índices respiratorios tradicionales tienen capacidad limitada cuando se emplean individualmente. La ecografía diafragmática, el flujo máximo de tos, la presión inspiratoria máxima y modelos como VISAGE pueden mejorar la estratificación, aunque requieren validación adicional. La decisión debe ser individualizada y multidimensional.
Question: Predictores de Extubación en neurocritico
Read the full reviewThree-dimensional prediction of T-cell receptor–peptide–major histocompatibility complex (TCR–pMHC) structures has progressed substantially, but accuracy remains dependent on the modeling strategy, complex type, structural feature, and evaluation metric. Flexible-backbone docking, specialized comparative-modeling pipelines, multimeric deep-learning architectures, and ensemble-generation methods have each addressed distinct limitations. TCRpMHCmodels, TCRmodel2, AlphaFold2, and AlphaFold3 have shown strong performance in different settings, while HADDOCK and specialized docking protocols can benefit from informative interface restraints or characteristic TCR–pMHC geometry. Nevertheless, CDR3 loops, peptide positioning, docking orientation, interface geometry, MHC class II complexes, and binding-affinity or specificity inference remain difficult. Global structural similarity may therefore obscure biologically important local errors. Current predictors are most appropriately used as complementary, hypothesis-generating tools, with model assessment based on multiple global, interface-focused, and functional criteria and with experimental validation retained as an essential step.
Question: performance of 3d structure prediction methods on TCR-pMHC complexes
Read the full reviewThe supplied evidence indicates that pioglitazone and related PPARγ agonists promote adipogenic remodeling, but it does not resolve whether they recruit primitive adipose stem cells, commit previously uncommitted progenitors, or primarily differentiate pre-existing committed preadipocytes. The strongest direct evidence is a short-term deuterium-labeling study showing increased generation of cells in both mature adipocyte and stromal-vascular compartments during pioglitazone exposure, consistent with precursor involvement and new adipocyte production (PMID: 22124466). However, the heterogeneous stromal-vascular fraction, absence of lineage tracing, and limited treatment duration prevent identification of the responsible progenitor population or assessment of long-term self-renewal. Related studies support PPARγ-dependent adipogenic differentiation, matrix remodeling, and possible clonal expansion in experimental systems, but remain indirect for pioglitazone action in normal human adipose tissue (PMID: 16799780; PMID: 16873539; PMID: 21572083; PMID: 12529376; PMID: 28957413). Overall, differentiation of adipogenically competent precursor cells is the best-supported interpretation, whereas recruitment of primitive stem cells and preservation of durable progenitor self-renewal remain unproven.
Question: does pioglitazone recruit proliferating adipose stem cells, commit uncommitted progenitors, or merely terminally differentiate an existing committed preadipocyte pool? what evidence from lineage tracing, deuterium labeling, clonal analysis, or serial human biopsies indicates whether chronic treatment preserves progenitor self-renewal and long-term hyperplastic capacity?
Read the full reviewPioglitazone improves insulin sensitivity and promotes subcutaneous adipose storage, but its ability to preferentially increase femoral rather than abdominal adipogenesis remains incompletely established. Human evidence indicates that pioglitazone can stimulate formation of new adipocytes in femoral subcutaneous fat while reducing relative visceral adiposity in women with obesity, although other studies demonstrate increased total subcutaneous fat without proving femoral selectivity (PMID: 33001232; PMID: 11887166; PMID: 12050251; PMID: 19910937; PMID: 21272186). Potential complementary pathways include adiponectin–AMPK signaling, 11β-HSD1/cortisol reduction, dietary fatty-acid optimization, BMP-mediated progenitor recruitment, angiogenesis, extracellular-matrix remodeling, insulin signaling, FGF21, and α2-adrenergic mechanisms. Adiponectin–AMPK offers the best balance of metabolic plausibility, reversibility, and safety, whereas depot-targeted BMP signaling has the greatest theoretical selectivity but limited translational support. Reducing abdominal glucocorticoid drive may improve the femoral-to-abdominal ratio indirectly by restraining abdominal expansion. No cited human study has directly tested these combinations or established a femoral-to-abdominal adipogenesis ratio. Accordingly, these strategies remain hypothesis-generating and should prioritize regional adipose measurements, edema surveillance, fibrosis assessment, and progenitor biology.
Question: which modifiable pathways could synergize with pioglitazone to increase the femoral-to-abdominal adipogenesis ratio—α2-adrenergic signaling, 11β-HSD1/cortisol, insulin, adiponectin–AMPK, FGF21, BMP signaling, angiogenesis, extracellular-matrix remodeling, or specific dietary fatty acids? rank candidates by depot selectivity, human evidence, expected effect size, reversibility, and risks such as generalized fat gain, edema, fibrosis, or progenitor depletion.
Read the full reviewDifferential responsiveness to pioglitazone among human adipose progenitors is best interpreted as variation in PPARγ pathway competence within distinct depot-specific developmental and cellular contexts. The available evidence does not support total PPARG abundance, or alternative PPARG isoform usage alone, as a sufficient explanation. Instead, PPARG2 induction and activity, RXR heterodimer competence, adipogenic commitment, BMP–WNT signaling, developmental identity, extracellular-matrix properties, and inflammatory or vascular context may interact to establish different thresholds for terminal adipogenesis. The strongest direct evidence concerns depot-dependent adipogenic competence and WNT-related regulation, including LRP5-associated effects in paired gluteal and abdominal progenitors (PMID: 25651180). Evidence from subcutaneous–omental comparisons further indicates that PPARG expression, PPARG2 inducibility, and RXRα availability may contribute, although these findings remain an extrapolation for femoral/gluteal–abdominal comparisons (PMID: 11872672; PMID: 9399962). Overall, pioglitazone appears to act on pre-existing depot states rather than uniformly overcoming upstream constraints.
Question: in paired human femoral/gluteal and abdominal adipose progenitors, which molecular features explain differential responsiveness to pioglitazone—PPARG abundance or isoforms, RXR/coactivator availability, CEBPA, ZNF423, BMP–WNT signaling, HOX/TBX15 developmental identity, extracellular-matrix stiffness, vascularity, or inflammatory state—and which of these features are plausibly modifiable in vivo?
Read the full review